Develops and manufactures biosimilar versions of major biologic drugs for global markets.
Develops and manufactures biosimilar versions of major biologic drugs for global markets.
Sells through marketing partners in each region instead of building its own sales force: it supplies the drug and shares in the sales, and also receives milestone payments when products are approved or launched. Its manufacturing is based in Reykjavik, Iceland. Founded by Robert Wessman, linked to Alvogen.
Moat: narrow (regulatory licence, scale, process know-how). In-house biosimilar manufacturing at scale, but competes on price against multiple approved biosimilars.
Headquarters: Reykjavik, Iceland · Founded: 2013 · Employees: 1,460
Size Alvotech (ALVO) is a United States Health Care company (Biotechnology) with a market value of $1.62B, the 1909th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.55 on 18 Nov 2026.
Performance Over six months the shares gained 37.9%, against -11.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 14.2% over the last twelve months (peer median +24.9%); the operating margin is 11.5% (peer median 3.4%).
Valuation It trades at 22.6× forward earnings against a peer median of 37.0× (4th cheapest of 9).
Capital Return on invested capital runs 2.5 points below its cost of capital (6.1% WACC).
Short interest Short interest is 1.6% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $490M | $586M | $490M | $91.4M | $83.0M |
| Revenue growth | — | +20% | +436% | +10% | — |
| Gross profit | $278M | $335M | $292M | -$78.0M | $8.58M |
| EBITDA | $98.7M | $113M | $98.6M | -$331M | -$325M |
| Net income | -$249M | $27.9M | -$232M | -$552M | -$514M |
| Free cash flow | -$318M | -$115M | -$291M | -$345M | -$350M |
| Capital expenditure | $144M | $96.1M | $57.0M | $46.5M | $49.0M |
| Total debt | $1.56B | $1.45B | $1.19B | $1.08B | $805M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alvotech ALVO | $1.62B | +38% | -14% | 12% | 22.6× | n/a |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALVO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.1% | -7.1% | 8th lowest of 21 |
| 6-month return | +37.9% | -11.9% | 3rd highest of 20 |
| Distance from 52-week high | -30.3% | -44.5% | 4th highest of 21 |
| Revenue growth (TTM) | -14.2% | +24.9% | 4th lowest of 19 |
| Operating margin | 11.5% | 3.4% | 8th highest of 19 |
| Forward P/E | 22.6× | 37.0× | 4th cheapest of 9 |
| ROIC minus cost of capital | -2.5 pp | -5.9 pp | 7th highest of 15 |
| EV / EBITDA | 31.6× | 8.5× | 2nd most expensive of 6 |
| Net debt / EBITDA | 15.2× | -1.1× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |